Leptomeningeal metastases from lung adenocarcinoma
Conditions
Interventions
The group that underwent ventriculoperitoneal shunt placement.:None
Control group:None
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with leptomeningeal metastases (including brain tissue metastases) from lung adenocarcinoma according to the 2023 ELANO-ESMO guideline criteria. 2. Ventriculoperitoneal shunt group: patients who underwent ventriculoperitoneal shunt placement. 3. Non-Ventriculoperitoneal Shunt Group: patients who did not receive Ventriculoperitoneal shunt placement.
Exclusion criteria
Exclusion criteria: 1. Patients with non-driver gene-positive mutant lung adenocarcinoma or those with concurrent other malignant tumors; 2. Patients with incomplete clinical data or who were lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival Comparison: Surgical vs Non-Surgical Groups in Driver Gene-Positive Lung Adenocarcinoma Patients with Leptomeningeal Metastasis Undergoing Ventriculoperitoneal Shunt; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival Comparison: Surgical vs Non-Surgical Groups in Driver Gene-Positive Lung Adenocarcinoma Patients with Leptomeningeal Metastasis Undergoing Ventriculoperitoneal Shunt;Overall survival rate (at 6 months, 1 year, and 2 years);Intracranial progression-free survival rate (at 6 months, 1 year, and 2 years); | — |
Countries
China
Contacts
Public ContactQingsheng Xu
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed